Drug or intervention
Moxifloxacin Clinical Trials
Studies that test Moxifloxacin, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 58Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
This is a Phase 3, randomized, open-label, active-controlled, multicenter trial evaluating the efficacy, safety, and tolerability of quabodepistat-containing regimens for the treatment of rifampicin-resistant or…
- Trial name
- QUANTUM-TB (NCT07209761)
- Testing
- Bedaquiline, Quabodepistat, Pretomanid
- Where
- 42 sites in China, Georgia and 8 more
- Volunteers
- 532 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Brucellosis, Osteoarticular Brucellosis
All-Oral Fluoroquinolone-Based Triple Therapies for Adults With Imaging-Confirmed Osteoarticular Brucellosis
Brucellosis is a globally distributed zoonosis with persistent clinical management challenges. The World Health Organization (WHO)-recommended doxycycline-rifampin (DOX-RIF) dual regimen may drive rifampin-associated…
- Trial name
- BRUCE-O (NCT07887152)
- Testing
- Doxycycline + Rifampicin + Ceftriaxone (intravenous therapy for 4 weeks), Triple oral regimen (Doxycycline + Rifampicin + Levofloxacin), Triple oral regimen (Doxycycline + Rifampicin + Moxifloxacin)
- Volunteers
- 150 people
- Sponsor
- The First Affiliated Hospital of Shihezi University
Brucellosis
Fluoroquinolone-Doxycycline Oral Treatments for Adults With Uncomplicated Brucellosis
Brucellosis is a common zoonotic infectious disease. The standard dual regimen of doxycycline combined with rifampicin is widely used for uncomplicated brucellosis.
- Trial name
- BRUCE-U (NCT07887126)
- Testing
- Doxycycline + Rifampicin, Doxycycline + Levofloxacin, Doxycycline + Moxifloxacin
- Where
- 3 sites in China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital of Shihezi University
Tuberculous Meningitis, HIV
BPaLMZ for TB Meningitis
This two-stage study will compare consented research participants with tuberculous meningitis receiving experimental Bedaquiline (B), Pretomanid (Pa), Linezolid (L); Moxifloxacin (M), Pyrazinamide (Z) known as (BPaLMZ) to…
- Conditions
- Tuberculous Meningitis, HIV, Meningitis, TB - Tuberculosis
- Trial name
- BPaLMZ (NCT07227779)
- Testing
- BPaLMZ Regimen
- Where
- 2 sites in Uganda
- Volunteers
- 312 people
- Sponsor
- David Boulware
Odontogenic Infection, Maxillofacial Infection
Moxifloxacin Versus Clindamycin in the Management of Odontogenic Maxillofacial Infectious Processes
Investigators are conducting a trial to compare moxifloxacin against clindamycin for dental infections that spread to the face and jaw.
- Conditions
- Odontogenic Infection, Maxillofacial Infection, Cellulitis, Cellulitis of Face
- Trial name
- NCT07810244
- Testing
- Clindamycin, Moxifloxacin (400 mg)
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Nishtar Medical University
Healthy Participants
A Single and Multiple Ascending Dose Study of EPX-100 in Healthy Adult Participants
A study to evaluate the safety and tolerability of single and multiple ascending doses of EPX-100 in healthy adult participants.
- Trial name
- NCT07879170
- Testing
- EPX-100, Moxifloxacin
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Epygenix
Pulmonary Tuberculosis
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
The UNITE4TB consortium is a group of universities and pharmaceutical companies funded by the European Union. This consortium are carrying out a trial to find better and faster ways to treat tuberculosis (TB).
- Trial name
- PARADIGM4TB (NCT06114628)
- Testing
- Ganfeborole, BTZ-043, Bedaquiline (B)
- Where
- 11 sites in Moldova, South Africa and 3 more
- Volunteers
- 2,500 people
- Sponsor
- University College, London
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives
The purpose of the study is to evaluate the pharmacokinetic effects and safety and tolerability of VX-407 when coadministered with oral contraceptives.
- Trial name
- NCT07792408
- Testing
- VX-407, LNG/EE, NGM/EE
- Where
- Canada
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cataract, Postoperative Endophthalmitis
Intracameral Levofloxacin Versus Moxifloxacin After Cataract Surgery
This randomized study aims to compare the safety and efficacy of intracameral levofloxacin versus intracameral moxifloxacin administered at the end of phacoemulsification cataract surgery.
- Trial name
- NCT07850414
- Testing
- Levofloxacin, Moxifloxacin
- Volunteers
- 93 people
- Sponsor
- Assiut University
Endophthalmitis
Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis
- Trial name
- NCT03244072
- Testing
- Moxifloxacin
- Where
- United States
- Volunteers
- 60,000 people, healthy volunteers welcome
- Sponsor
- Jason Ahee, M.D.
Completed, with results posted
All 140Acanthamoeba Keratitis, Fungal Keratitis
Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction
Rose Bengal Electromagnetic Activation with Green light for Infection Reduction (REAGIR ) is an international, randomized, doubled masked, clinical trial.
- Trial name
- REAGIR (NCT05110001)
- Testing
- Moxifloxacin Ophthalmic, Chlorhexidine Gluconate, Natamycin
- Where
- 2 sites in Brazil, India
- Volunteers
- 330 people
- Sponsor
- University of California, San Francisco
Tuberculosis
Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis
The Tuberculosis Trials Consortium (TBTC) Study 31 is a phase 3 trial evaluating rifapentine-containing regimens for treatment-shortening of drug-susceptible pulmonary tuberculosis.
- Trial name
- S31PK/PD (NCT02563327)
- Testing
- Rifapentine, Moxifloxacin, Rifampin
- Where
- 3 sites in United States, Uganda and 1 more
- Volunteers
- 2,516 people
- Sponsor
- Centers for Disease Control and Prevention
Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
To evaluate the efficacy, safety and tolerability at 8 weeks (2-months), 52 weeks (12-months), and 104 Weeks (24-months) post the start of the following treatment regimens in participants with: Drug Sensitive TB (DS-TB) patients…
- Conditions
- Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR, Tuberculosis
- Trial name
- NCT03338621
- Testing
- Pretomanid, Bedaquiline, Moxifloxacin
- Where
- 26 sites in Brazil, Georgia and 6 more
- Volunteers
- 455 people
- Sponsor
- Global Alliance for TB Drug Development
HIV-associated Tuberculosis
Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis
A5406 hypothesized that dolutegravir (DTG) 50 mg taken twice daily provides adequate exposures to maintain viral suppression when dosed with rifapentine (RPT) 1200 mg for HIV-associated tuberculosis (TB).
- Trial name
- NCT05630872
- Testing
- Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC, DTG 50 mg orally QD plus TDF/3TC, 2HPZM
- Where
- 4 sites in South Africa, Thailand
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis
Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis
This study measured the early bactericidal activity (EBA), safety, tolerability and pharmacokinetics of GSK3036656 in combination with either delamanid, bedaquiline or BTZ-043 and delamanid in combination with bedaquiline or…
- Trial name
- NCT05382312
- Testing
- GSK3036656, Bedaquiline, Delamanid
- Where
- South Africa
- Volunteers
- 127 people
- Sponsor
- GlaxoSmithKline